MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.540
-0.015
-0.96%
Opening 14:31 12/06 EST
OPEN
1.530
PREV CLOSE
1.555
HIGH
1.600
LOW
1.490
VOLUME
61.25K
TURNOVER
--
52 WEEK HIGH
4.210
52 WEEK LOW
1.380
MARKET CAP
61.06M
P/E (TTM)
-3.2083
1D
5D
1M
3M
1Y
5Y
We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 1d ago
BRIEF-Akari Therapeutics Reports Third Quarter 2021 Financial Results And Highlights Recent Clinical Progress
reuters.com · 3d ago
Akari Therapeutics reports Q3 results
Akari Therapeutics (NASDAQ:AKTX): Q3 GAAP EPS of $0.00. Press Release As of September 30, 2021, the company had cash of approximately $13.4M, compared to cash of approximately $14.1M at December
Seekingalpha · 3d ago
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
Sites opened in Phase III study of nomacopan in bullous pemphigoid (BP)Phase III study of nomacopan in severe pediatric hematopoietic stem cell...
Globe Newswire · 3d ago
Akari Therapeutics Highlights Presentation Of New Data Revealing Potential Mechanism Of Action Driving Serious Exacerbations Across Lung Disorders
Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia NEW YORK and LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc
Benzinga · 5d ago
Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit
NEW YORK and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leuko...
GlobeNewswire · 10/26 12:00
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye...
Globe Newswire · 10/25 12:30
BRIEF-Akari Therapeutics PLC Reports Q2 2021 Financial Results
reuters.com · 09/22 14:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKTX. Analyze the recent business situations of Akari through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AKTX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
High5.00
Average5.00
Low5.00
Current 1.540
EPS
Actual
Estimate
-0.45-0.33-0.20-0.08
Q3 2020
Q4 2020
    0
Q1 2021
  • 0
Q2 2021
Q3 2018
Institutional Holdings
Institutions: 24
Institutional Holdings: 2.15M
% Owned: 5.43%
Shares Outstanding: 39.65M
TypeInstitutionsShares
Increased
0
0
New
2
16.45K
Decreased
5
109.47K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.05%
Pharmaceuticals & Medical Research
-0.69%
Key Executives
Chairman/Executive Director
Ray Prudo
Chief Executive Officer/Chief Operating Officer/Director
Clive Richardson
Chief Financial Officer
Torsten Hombeck
Director
Michael Grissinger
Independent Director
David Byrne
Independent Director
Peter Feldschreiber
Independent Director
James Hill
Independent Director
Stuart Ungar
Independent Director
Donald Williams
No Data
  • All
  • Financials
  • Insiders
More
About AKTX
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid or leukotriene system and the bioamine system for the treatment of rare and orphan diseases. Its lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4 (LTB4). It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement. It inhibits LTB4 by capturing the fatty acid within the body of the nomacopan protein. The anaphylatoxin (C5a) and the membrane attack complex (MAC) cause and maintain a proinflammatory and prothrombotic state. LTB4 also activates cells via two separate GPCRs and can independently cause and maintain a proinflammatory state.

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.